Performance of the 6 RAMs (N = 806)
| . | Khorana score8 . | PROTECHT13 . | CONKO15 . | COMPASS-CAT14 . | CATScore16 . | EHR-CAT17 . |
|---|---|---|---|---|---|---|
| C-statistics at 180 days (95% CI) | 0.53 (0.50-0.56) | 0.58 (0.56-0.61) | 0.54 (0.51-0.57) | 0.50 (0.47-0.53) | 0.65 (0.62-0.67) | 0.55 (0.52-0.57) |
| High-risk patients, n (%) | 76 (9.4) | 208 (25.8) | 80 (9.9) | 493 (61.2) | 147 (18.2) | 505 (62.7) |
| Cutoff for high risk (points) | ≥3 | ≥3 | ≥3 | ≥ 7 | ≥8% risk∗ | ≥3 |
| Intermediate-risk patients, n (%) | 405 (50.3) | NA | NA | NA | NA | NA |
| Cutoff for intermediate risk (points) | 2 | NA | NA | NA | NA | NA |
| Low-risk patients, n (%) | 325 (40.3) | 598 (74.2) | 726 (90.1) | 313 (38.8) | 659 (81.8) | 301 (37.3) |
| Cutoff for low risk (points) | <2 | <3 | <3 | <7 | <3 | |
| 6-Month VTE incidence in high-risk patients, % (95% CI) | 17.1 (8.6-25.6) | 15.9 (10.9-20.8) | 18.8 (10.2-27.3) | 10.3 (7.7-13.0) | 19.7 (13.3-26.2) | 12.1 (9.2-14.9) |
| 6-Month VTE incidence in intermediate-risk patients, % (95% CI) | 10.9 (7.8-13.9) | NA | NA | NA | NA | NA |
| 6-Month VTE incidence in low-risk patients, % (95% CI) | 10.2 (6.9-13.4) | 9.5 (7.2-11.9) | 10.3 (8.1-12.5) | 12.5 (8.8-16.1) | 9.3 (7.0-11.5) | 9.6 (6.3-13.0) |
| Gray P value (difference between the VTE cumulative incidence in the high-risk and low-risk groups) | .024 | .016 | .025 | .394 | .001 | .355 |
| Gray P value (difference between the VTE cumulative incidence in the high-risk and intermediate-risk groups) | .268 | NA | NA | NA | NA | NA |
| SHR for VTE occurrence in high-risk patients compared with low-risk patients | 1.69 (0.89-3.18) | 1.68 (1.10-2.58) | 1.88 (1.08-3.27) | 0.84 (0.55-1.26) | 2.19 (1.41-3.39) | 1.23 (0.79-1.90) |
| SHR for VTE occurrence in intermediate-risk patients compared with low-risk patients | 1.04 (0.67-1.63) | NA | NA | NA | NA | NA |
| . | Khorana score8 . | PROTECHT13 . | CONKO15 . | COMPASS-CAT14 . | CATScore16 . | EHR-CAT17 . |
|---|---|---|---|---|---|---|
| C-statistics at 180 days (95% CI) | 0.53 (0.50-0.56) | 0.58 (0.56-0.61) | 0.54 (0.51-0.57) | 0.50 (0.47-0.53) | 0.65 (0.62-0.67) | 0.55 (0.52-0.57) |
| High-risk patients, n (%) | 76 (9.4) | 208 (25.8) | 80 (9.9) | 493 (61.2) | 147 (18.2) | 505 (62.7) |
| Cutoff for high risk (points) | ≥3 | ≥3 | ≥3 | ≥ 7 | ≥8% risk∗ | ≥3 |
| Intermediate-risk patients, n (%) | 405 (50.3) | NA | NA | NA | NA | NA |
| Cutoff for intermediate risk (points) | 2 | NA | NA | NA | NA | NA |
| Low-risk patients, n (%) | 325 (40.3) | 598 (74.2) | 726 (90.1) | 313 (38.8) | 659 (81.8) | 301 (37.3) |
| Cutoff for low risk (points) | <2 | <3 | <3 | <7 | <3 | |
| 6-Month VTE incidence in high-risk patients, % (95% CI) | 17.1 (8.6-25.6) | 15.9 (10.9-20.8) | 18.8 (10.2-27.3) | 10.3 (7.7-13.0) | 19.7 (13.3-26.2) | 12.1 (9.2-14.9) |
| 6-Month VTE incidence in intermediate-risk patients, % (95% CI) | 10.9 (7.8-13.9) | NA | NA | NA | NA | NA |
| 6-Month VTE incidence in low-risk patients, % (95% CI) | 10.2 (6.9-13.4) | 9.5 (7.2-11.9) | 10.3 (8.1-12.5) | 12.5 (8.8-16.1) | 9.3 (7.0-11.5) | 9.6 (6.3-13.0) |
| Gray P value (difference between the VTE cumulative incidence in the high-risk and low-risk groups) | .024 | .016 | .025 | .394 | .001 | .355 |
| Gray P value (difference between the VTE cumulative incidence in the high-risk and intermediate-risk groups) | .268 | NA | NA | NA | NA | NA |
| SHR for VTE occurrence in high-risk patients compared with low-risk patients | 1.69 (0.89-3.18) | 1.68 (1.10-2.58) | 1.88 (1.08-3.27) | 0.84 (0.55-1.26) | 2.19 (1.41-3.39) | 1.23 (0.79-1.90) |
| SHR for VTE occurrence in intermediate-risk patients compared with low-risk patients | 1.04 (0.67-1.63) | NA | NA | NA | NA | NA |
NA, not applicable.
Refers to the calculated 6-month VTE risk.